United States securities and exchange commission logo




                                                                                
                        March 28, 2024

       Kiran Asarpota
       Chief Operating Officer
       ASLAN Pharmaceuticals Ltd
       3 Temasek Avenue
       Level 18 Centennial Tower
       Singapore 039190

                                                        Re: ASLAN 
Pharmaceuticals Ltd
                                                            Registration 
Statement on Form F-3
                                                            Filed March 25, 
2024
                                                            File No. 333-278217

       Dear Kiran Asarpota:

              This is to advise you that we have not reviewed and will not 
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for 
acceleration. We remind you
       that the company and its management are responsible for the accuracy and 
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of 
action by the staff.

                                                        Please contact Jimmy 
McNamara at 202-551-7349 with any questions.



                                                                                
                        Sincerely,

                                                                                
                        Division of Corporation Finance
                                                                                
                        Office of Life Sciences
       cc:                                              Carlos Ramirez